A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions; Therapeutic Use
- Acronyms DAISS
- Sponsors Ferring Pharmaceuticals
- 08 Feb 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 06 Mar 2014 Planned end date changed from 1 Oct 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.